1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6A5087207494EFA8100258A2B00528F76
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/leveraging-medical-analytics-to-improve-strategy-launch-outcomes-care-models?opendocument
18
19opendocument
2044.221.66.130
21
22
23best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Data Management and Biostatics

Leveraging Medical Analytics to Improve Strategy, Launch, Outcomes and Care Models

ID: POP-369


Features:

21 Info Graphics

16 Data Graphics

240+ Metrics

17 Narratives


Pages: 46


Published: 2023


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
High-impact Medical Affairs organizations are harnessing the potential of advanced analytics to address critical unmet needs, redefine strategies, optimize product launches, and enhance patient outcomes and care models. However, the pace of advancement remains uneven among competitors, due in many cases to resource constraints, regulatory uncertainty, or lack of technical expertise in expanding Medical Analytics capabilities.

Best Practices, LLC undertook this benchmarking research to explore how Medical Affairs groups are growing the use of analytics, gaining organizational support for higher investment, and achieving strategic goals by means of both big and small data analysis. This report will serve as a reference point for Medical Affairs leaders to unlock the full potential of Medical Analytics and propel their organization to new heights in better strategy, enhanced care models and improved outcomes which support unmet needs.

Video Brief:


Industries Profiled:
Health Care; Biotech; Biopharmaceutical; Pharmaceutical; Medical Device; Manufacturing; Consumer Products; Diagnostic; Communications; Science


Companies Profiled:
Acadia Healthcare; Amicus Therapeutics; Apellis Pharmaceuticals; ASC Therapeutics; Astellas; AstraZeneca; Baxter International; Bayer; Biogen; bioMerieux; Boehringer Ingelheim; Daiichi Sankyo; Dompé; Eisai; Eli Lilly and Company; Envista; GE Healthcare; Grifols; Janssen; Kyowa Kirin; Merck Sharp & Dohme; Merz Aesthetics; Myovant Sciences; Nobel Biocare; Novartis; Novo Nordisk; Organon; Roche; Sumitomo Pharma; Sunovion; Symbiotix; Teva Pharmaceutical Industries Ltd; Thermo Fisher Scientific; Unilab; Varian; Xeris Pharmaceuticals

Study Snapshot

Best Practices, LLC engaged 41 Medical Affairs leaders from 38 leading biopharma organizations. A range of functional leaders were targeted to capture the diverse strategies and analytical needs across the industry. Functions represented by this study include: Medical Operations, Medical Excellence, Digital & Medical Analytics, HEOR, Field Medical, Medical Communications, Medical Info, Strategic Insights, and other Senior Medical Leadership. Best Practices LLC also conducted deep-dive interviews with Medical Affairs & Analytics leaders at 9 organizations to capture additional insights.

Key topics covered in this report include:

  • Organizational Goals of Using Medical Analytics
  • Current Uses of Medical Analytics to Support Key Activities
  • Big vs. Small Data Utilization
  • Key Data Sources and Impact
  • Average Maturity of Analytics Support for Medical Affairs
  • Justifying Investment for Increased Resources
  • Sources of Medical Analytics Expertise
  • Effective Structure of Medical Analytics Groups
  • Staffing and Resourcing

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Organizational Goals for Medical Analytics: Biopharma manufacturers are seeking to maximize Medical impact through insights generation (81%), enhanced customer interactions (63%), and omnichannel engagement (51%) fueled by a strategic Medical Analytics capability.
  • Advancing Adoption: 85% of companies believe Medical Analytics can accelerate adoption and care model change but picking the right pilot is an art.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive SummaryPg. 3-13
II.
Leveraging Analytics in Medical AffairsPg. 14-22
III.
Growth Areas for Medical AnalyticsPg. 23-30
IV.
Next Steps for Building a Successful Medical Analytics CapabilityPg. 31-37
V.
Key Insights & Lessons LearnedPg. 38-42
VI.
Participant DemographicsPg. 43-45
VII.
About Best Practices, LLCPg. 46

    List of Charts & Exhibits

    I. Executive Summary

    • Benchmark study partner companies
    • One-page research summary
    • One-page FAQ for leaders to address commonly asked questions about growing analytics capabilities within Medical Affairs
    • Data summary
    • Data strategy
    • SWOT assessment
    • Key lessons learned
    • Analytics KPIs

    II. Leveraging Analytics in Medical Affairs

    • Hierarchy of analytics: Types and impact of analytics with examples
    • Small vs. big data sets
    • Top organizational goals for Medical Analytics
    • Key data sources used by Medical organizations
    • Case successes: Impact and efficiency driven by Analytics on 3 critical fronts
    • Data strategy

    III. Growth Areas for Medical Analytics

    • Current maturity of Analytics for external engagement
    • Current maturity of Analytics for enhanced Medical value
    • Analytics maturity curve
    • Current maturity of Analytics: Internal activities and resourcing activities
    • Tips and considerations for accelerating adoption and care model change
    • Advancing adoption
    • Uses of AI in post-ChatGPT world

    IV. Next Steps for Building a Successful Medical Analytics Capability

    • Hallmarks of maturity of Medical Analytics groups
    • Bridging the gap
    • Structure and staffing of Medical Analytics groups
    • Launching Medical Analytics
    • Justifying Medical Analytics investment

    V. Key Insights & Lessons Learned

    • FAQ checklist for Medical Analytics leadership teams
    • Full SWOT assessment
    • Key lessons learned
    • Analytics KPIs

    VI. Participant Demographics

    • Therapeutic areas represented by benchmark companies
    • Geographic responsibilities of benchmark partners